DAFTAR PUSTAKA American Medical Association, 2008. American Medical Association Complete Guide to Prevention and Wellness. Wiley, United State of America. American Cancer Society, 2014. 'How is breast cancer staged?'. URL: http://www.cancer.org /cancer/ breastcancer/ detailedguide/breast-cancerstaging (diakses tanggal 6/3/2014). Badan Penelitian dan Pengembangan Kesehatan, 2007. 'Laporan Nasional Riskesdas 2007. URL: http://www.litbang.depkes.go.id/bl_riskesdas2007 (diakses tanggal 3/3/2014). Badan Penelitian dan Pengembangan Kesehatan, 2013. 'Laporan Nasional Riskesdas 2007. URL: http://www.litbang.depkes.go.id/bl_riskesdas2007 (diakses tanggal 3/3/2014). Bodicoat, D.H., Schoemaker, M.J., Jones, M.E., McFadden, E., Griffin, J., Ashworth, A., dkk., 2014. Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. Breast cancer research: BCR, 16: R18. Carrison, R., 2014. 'National Comprehensive Cancer Network : Adjuvant Therapy Chemotherapy, Hormonal Therapy' Medscape Pharmacists. URL: https://www.google.com/#q=hormonal+therapy+algorithm+for+breast+ca ncer (diakses tanggal 3/4/2014). Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., dkk., 2004. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. New England Journal of Medicine, 350: 1081–1092. Cummings, F.J., 2002. Evolving uses of hormonal agents for breast cancer therapy. Clinical Therapeutics, 24, Supplement 3: C3–C25. Dranitsaris, G., Verma, S., dan Trudeau, M., 2003. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase
83
inhibitors to tamoxifen. American journal of clinical oncology, 26: 289– 296. Fauci, A.S., 2008. Harrison’s Principles of Internal Medicine Editors, Anthony S. Fauci ... [et Al.]., 17th ed. McGraw-Hill Medical, New York. Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., dan Parkin, D.M., 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 127: 2893–2917. Gordon, B.L., Shaw, H.S., Kroll, D.J., dan Daniel, B.R., 2010. Breast Cancer Recurrence and Advanced Disease: Comprehensive Expert Guidance. Duke University Press, United State of America. Hans, P., 2010. Medical Management of Advance Disease, dalam: Reed, M.W., Audisio, R.A. (Eds.), Springer, New York, hal. 300–303. Hastuti, S. dan Dwiprahasto, I., M.M.S., 2012. 'Analisis Hubungan Jenis Kemoterapi dengan Perbaikan Outcome dan Biaya Pengobatan pada Pasien Kanker Payudara DI RSUD DR. Moewardi'. Universitas Gadjah Mada, Yogyakarta. Helms, R.A. dan Quan, D.J., 2006. Textbook of Therapeutics: Drug and Disease Management, 8th ed. Lippincott Williams & Wilkins, Philadelphia, hal. 2773-2778. Josefsson, M.L. dan Leinster, S.J., 2010. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy. The Breast, 19: 76–83. Kementerian Kesehatan, 2013. 'buletin ed mei okk - Penelusuran Google'. URL: https://www.google.com/#q=buletin+ed+mei+okk
(diakses
tanggal
4/3/2014). Kementerian Kesehatan, 2014. Kementrian Kesehatan Republik Indonesia'. URL: www.depkes.go.id/index.php?vw=2&id_1309000001
(diakses
tanggal
7/5/2014). Kenne, E., Öhlén, J., Jonsson, T., dan Gaston-Johansson, F., 2007. Coping with Recurrent Breast Cancer: Predictors of Distressing Symptoms and Health-
84
Related Quality of Life. Journal of Pain and Symptom Management, 34: 24–39. Massimini, G., Paridaens, R., Lobelle, J., dan Piscitelli, G., 2003. 'Breast cancer hormonal therapy'. 20030144259. National Cancer Institute, 2013. 'Breast Cancer Treatment (PDQ®) - National Cancer Institute' Treatment Option Overview. URL: http://www.cancer.gov /cancertopics/pdq/treatment/breast/Patient/page5
(diakses
tanggal
9/3/2014). Noe, L.L., Becker 3rd, R.V., Gradishar, W.J., Gore, M., dan Trotter, J.P., 1999. The cost effectiveness of tamoxifen in the prevention of breast cancer. The American journal of managed care, 5: S389–406. Otto, S., 2013. Keperawatan Onkologi. EGC, Jakarta. Puhalla, S., Bhattacharya, S., dan Davidson, N.E., 2012. Hormonal therapy in breast cancer: A model disease for the personalization of cancer care. Molecular Oncology, 6: 222–236. Puspandari, D.A,. 2014. Model Estimasi Biaya Obat Pasien Kanker Payudara Dan Faktor Penentu Di Rumah Sakit Di Indonesia, Disertasi, Dr., Unversitas gadjah Mada, Yogyakarta. Rafferty, E., 2009. Multidisciplinary Issues for Newly Diagnosed, dalam: MD, J.K.E., Phd, B.L.S.M., PhD, A.G.T.M. (Eds.), Breast Cancer: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing, hal. 67–82. Rao, S., Kubisiak, J., dan Gilden, D., 2004. Cost of Illness Associated with Metastatic Breast Cancer. Breast Cancer Research and Treatment, 83: 25– 32. Risebrough, N.A., Verma, S., Trudeau, M., dan Mittmann, N., 2007. Costeffectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer, 110: 499–508. Sanchez, A, 2008. pharmacoeconomics principles methods and applications. The Mc-Graw Hills Companys, 1.
85
Setiawan, D. dan Dwiprahasto, I., M.M.S., 2011. 'Biaya Pengobatan Pasien Kanker Payudara Stadium Awal Yang Mendapatkan Kemoterapi Kombinasi 5Fluorourasil, Doksorubisin, Siklofosfamid (FAC) Dengan Keoterapi Kombinasi Berbasis Taxan'. Universitas Gadjah Mada. Sewell, M dan Marczak, M, 2014. 'Using cost analysis in evaluation' The University of
Tucson
Arizona.
URL:
https://www.google.com.br/search?
q=using+cost+analysis+in+evaluation+sewel+2009&hl=id&authuser=0 (diakses tanggal 10/3/2014). Stopeck, A., 2014. Breast Cancer Treatment & Management. medscape,. Swart R, 2013. Adjuvant Therapy for Breast Cancer. Thompson, D., Taylor, D.C.A., Montoya, E.L., Winer, E.P., Jones, S.E., dan Weinstein, M.C., 2007. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value in Health, 10: 367–376. Tim Dharmais, R.K., 2003. Penatalaksanaan Kanker Payudara Terkini, 1st ed. Yayasan Obor Indonesia, Jakarta. Tobin, M., 2003. Breast Cancer, dalam: Taylor, R.B. (Ed.), Family Medicine: Principles and Practice. Springer, New York, hal. 903–907. Thurlimann, D., Taylor, D.C.A., Montoyo, E.l., Winer, E.P., Jones, S.E., dan Weinstein, M.C., 2007. Cost-Effectiveness of Switching to Exemestene after 2 to Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value in Health, 10: 367-376. Tsu, V.D., Jeronimo, J., dan Anderson, B.O., 2013. Why the time is right to tackle breast and cervical cancer in low-resource settings. Bulletin of the World Health Organization, 91: 683–690. Venturini, F dan Jhonson, A, 2002. Introduction to pharmacoeconomic principles and application in pharmacy practice. California journal of health system, 14.1: 6–15. Vogenberg, F.R., 2001. Introduction to Applied Pharmacoeconomics. McGrawHill, Medical Pub. Division.
86
Walley, T., Haycox, A., dan Boland, A., 2004. Pharmacoeconomics. Churchill Livingstone, Edinburgh; New York. Wang, Y., Atkins, D., Foekens, A.J., dan Klijn, G.M.J., 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet, 365: 1687–1717. World Health Organization, 2014. 'WHO | Breast cancer: prevention and control' WHO. URL: http://www.who.int/cancer/detection/breastcancer/en/index1. html (diakses tanggal 3/3/2014). Yueniwati, Y., Diana, N., Iskandar, A., 2007. Akurasi metode radiokolloid dan blue dye dalam mnedeteksi limfonodi sentinel dalam mendeteksi kanker payudara stadium dini. Jurnal Kedokteran Brawijaya, XXIII No.1: .
87
